Research programme: anti-bacterial therapeutics - BlueWillow Biologics
Alternative Names: NB-401; NB-402; Topical nanoemulsions for bacterial infections - BlueWillow Biologics; Vaginitis nanoemulsion (NB Prototype-1); Vaginitis nanoemulsion (NB Prototype-2)Latest Information Update: 25 Nov 2019
At a glance
- Originator NanoBio Corporation
- Developer BlueWillow Biologics; University of Michigan Medical School
- Class Antibacterials
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Burn infections; Cystic fibrosis-associated respiratory tract infections; Methicillin-resistant Staphylococcus aureus infections; Vaginitis; Wound infections
Most Recent Events
- 25 Nov 2019 Discontinued - Preclinical for Burn infections in USA (Topical)
- 25 Nov 2019 Discontinued - Preclinical for Cystic fibrosis-associated respiratory tract infections in USA (Inhalation)
- 25 Nov 2019 Discontinued - Preclinical for Methicillin-resistant Staphylococcus aureus infections in USA (Intranasal)